Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery

Inventia Life Science, a world leader in advanced cell models for biomedical research and drug discovery, today announced a collaboration with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) using Inventia’s RASTRUM™ 3D cell culture platform. Through this collaboration, novel bioprinting capabilities offered by RASTRUM™ will be utilised to create 3D in vitro models for the preclinical screening of neurodegenerative disease therapeutic candidates.

Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery

Image Credit: Inventia Life Science

Inventia is committed to working with MSD to establish better in vitro models for neurodegenerative diseases. By working together, we aim to establish new approaches to drug discovery and create more translatable models which bridge the gap between in vitro and in vivo preclinical studies.”

Dr Julio Ribeiro, Founder and CEO, Inventia

The RASTRUM™ platform is designed to enable the generation of highly reproducible cell models that closely mimic the human brain. The collaboration aims to accelerate the drug discovery process by evaluating therapeutic candidates on 3D in vitro models of various neurological disorders, including Alzheimer’s disease and Parkinson’s disease.

“This collaboration with Inventia leverages MSD’s deep expertise in neuroscience and drug discovery with Inventia’s novel 3D bioprinting platform to develop more relevant and translational models of the brain with the aim of enhancing preclinical screening for neurodegenerative disease candidates,” said Dr. Jill Richardson, Executive Director of Biology, MSD, London.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Inventia Life Science. (2023, February 16). Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery. AZoLifeSciences. Retrieved on February 23, 2024 from https://www.azolifesciences.com/news/20230216/Inventia-Life-Science-collaborates-with-MSD-to-develop-3D-advanced-cell-models-for-neurodegenerative-disease-drug-discovery.aspx.

  • MLA

    Inventia Life Science. "Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery". AZoLifeSciences. 23 February 2024. <https://www.azolifesciences.com/news/20230216/Inventia-Life-Science-collaborates-with-MSD-to-develop-3D-advanced-cell-models-for-neurodegenerative-disease-drug-discovery.aspx>.

  • Chicago

    Inventia Life Science. "Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery". AZoLifeSciences. https://www.azolifesciences.com/news/20230216/Inventia-Life-Science-collaborates-with-MSD-to-develop-3D-advanced-cell-models-for-neurodegenerative-disease-drug-discovery.aspx. (accessed February 23, 2024).

  • Harvard

    Inventia Life Science. 2023. Inventia Life Science collaborates with MSD to develop 3D advanced cell models for neurodegenerative disease drug discovery. AZoLifeSciences, viewed 23 February 2024, https://www.azolifesciences.com/news/20230216/Inventia-Life-Science-collaborates-with-MSD-to-develop-3D-advanced-cell-models-for-neurodegenerative-disease-drug-discovery.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post
You might also like...
Healthcare super fund HESTA directly invests in Inventia Life Science